Information You Need to kNow
Resources and expert insights on protecting patients from chemotherapy-induced neutropenia (CIN).
Expert Perspectives in CIN
Introduction on Chemotherapy-Induced Neutropenia
CONTACT US | SUBSCRIBE FOR UPDATES Expert PerspectivesIntroduction on Chemotherapy-Induced NeutropeniaVideo Transcript: Dr. Lyman: So I'm a medical oncologist and hematologist at the Fred Hutchinson Cancer Research Center currently. I've been working in...
Identifying CIN Unmet Need
CONTACT US | SUBSCRIBE FOR UPDATES Expert PerspectivesIdentifying CIN Unmet NeedVideo Transcript: Dr. Lyman: So we generally define neutropenia based on the neutrophil count, which is a percentage of the total white blood count. So it can either be...
Timely CIN Clinical Management
CONTACT US | SUBSCRIBE FOR UPDATES Expert PerspectivesTimely CIN Clinical ManagementVideo Transcript: Dr. Lyman: My own practice has historically been primarily breast cancer. Although I have, over the years, focused on other cancer types, lung cancer,...
Impact of Dose Delays, Decreases, Discontinuations on CIN Clinical Outcomes
CONTACT US | SUBSCRIBE FOR UPDATES Expert PerspectivesImpact of Dose Delays, Decreases, Discontinuations on CIN Clinical OutcomesVideo Transcript: Dr. Lyman: The impact of modifications in the chemotherapy dose and schedule of course vary with type of...
Neutropenia Vulnerability Gap Infographic
Click on image to view full Infographic
Patient Videos
Keeping My Chemo
CONTACT US | SUBSCRIBE FOR UPDATES Patient VideosKeeping My ChemoRecent Expert Perspective Videos
References List
Resources available online:
Read full article
Centers for Disease Control and Prevention. Information for health care providers. Preventing infections in cancer patients. Centers for Disease Control and Prevention website. Updated December 16, 2019. Accessed June 29, 2020.
Read full article
Cheng C, Gallagher EM, Yeh JY, Earl MA. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anticancer Drugs. 2014;25(8):964-969.
Read abstract
Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves the outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479-484.
Read full article
Crawford J, Denduluri N, Patt D, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2020;28(2):925-932.
Read full article
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237.
Read abstract
Epstein R, et al. Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): retrospective, longitudinal data analysis. 2020 ASCO Virtual Scientific Program. Abstract e19300.
Read full article
Gupta A, Abbasi B, Gupta S. Management of chemotherapy induced neutropenia—an unmet clinical need. Am J Biomed Sci & Res. 2019;4(5):313-318.
Read full article
Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the Medical Panel Expenditures Survey (MEPS). Cancer Invest. 2008;26(6):647-651.
Read abstract
Healthcare Cost and Utilization Project (HCUP). 2017. Agency for Healthcare Research and Quality, Rockville, MD. Accessed November 13, 2020.
Read full article
Li Y, Klippel Z, Shih X, Wang H, Reiner M, Page JH. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Cancer Chemother Pharmacol. 2016;77(4):703-712.
Read abstract
Lyman GH. Management of chemotherapy-induced neutropenia with colony-stimulating factors. European Oncology. 2008;4(2):13-17.
Read full article
Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99-108.
Read abstract
National Comprehensive Cancer Center. NCCN hematopoietic growth factors. Short-term recommendations specific to issues with COVID-19 (SARS-CoV-2). NCCN.org. Accessed August 20, 2020.
Read full article
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors (Version 1.2020). Published on January 27, 2020. Accessed June 29, 2020.
Read full article
Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552-e561.
Read abstract
Waller CF, Ranganna GM, Pennella EJ, et al. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol. 2019;98(5):1217-1224.
Read full article
